Cite
HARVARD Citation
Tantravahi, S. et al. (n.d.). A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza®) in patients with chronic myelomonocytic leukemia. Leukemia & lymphoma. 57 (10), pp. 2441-2444. [Online].